Neurocrine Biosciences, Inc.
Financials
Valuation Metrics
Neurocrine Biosciences, Inc.'s Market Cap is $14.70B. At end of 2025 it was $14.11B. Ranked #701 of 3,121 in US market (top 22%), #219 of 1,463 on NASDAQ (top 15%), #32 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.70B | US#701/3,121 Sec#32/266 |
| Revenue | $3.37B | US#1,113/3,121 Sec#31/266 |
| Net Income | $706M | US#687/3,121 Sec#26/266 |
| Total Assets | $5.36B | US#1,406/3,121 Sec#37/266 |
| Net Assets | $3.69B | US#851/3,121 Sec#33/266 |
| Employees | 2,000 | US#1,672/3,121 Sec#40/266 |
| Value | ||
| P/E | 20.84x | US#1,228/3,121 Sec#35/266 |
| P/B | 3.98x | US#2,053/3,121 Sec#122/266 |
| PEG | 0.20x | US#343/3,121 Sec#16/266 |
| P/S | 4.36x | US#2,212/3,121 Sec#71/266 |
| EV/EBITDA | 16.09x | US#1,698/3,121 Sec#43/266 |
| FCF Yield | 5.92% | US#1,273/3,121 Sec#41/266 |
| Profitability | ||
| ROE | 19.10% | US#633/3,121 Sec#33/266 |
| ROA | 13.16% | US#293/3,121 Sec#27/266 |
| Op. Margin | 23.38% | US#749/3,121 Sec#35/266 |
| Revenue Growth | 34.42% | US#360/3,121 Sec#59/266 |
| Earnings Growth | 102.56% | US#306/3,121 Sec#14/266 |
| Financial Health | ||
| Debt Ratio | 45.09% | US#509/3,121 Sec#137/266 |
| Total Debt | $402M | US#1,988/3,121 Sec#71/266 |
| FCF | $870M | US#642/3,121 Sec#28/266 |
| Cash | $332M | US#1,348/3,121 Sec#76/266 |
| Current Ratio | 1.87x | US#1,331/3,121 Sec#227/266 |
| Net Debt/EBITDA | 0.08x | US#614/3,121 Sec#36/266 |
| Performance | ||
| 1Y Return | 0.39% | US#1,598/3,121 Sec#175/266 |
| 1M Return | -5.99% | US#1,150/3,121 Sec#108/266 |
| From 52W High | -21.43% | US#1,386/3,121 Sec#98/266 |
| 1Y MDD | -21.17% | US#780/3,121 Sec#30/266 |
| Trading | ||
| Volume | 2,443,711 shares | US#1,514/3,121 Sec#166/266 |
| Trading Value | $362M | US#659/3,121 Sec#41/266 |
| Per Share | ||
| EPS | $7.02 | US#471/3,121 Sec#13/266 |
| BPS | $36.73 | US#706/3,121 Sec#12/266 |
Company Info
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.